Ella B. Cleveland Trust Grant Program

The Ella B. Cleveland Trust Grant Program is dedicated to advancing medical research with the specific aim of understanding, treating, curing, and alleviating the suffering caused by leukemia, muscular dystrophy, and cerebral palsy. This program aligns directly with the Trust's foundational mission to address critical health challenges and improve the quality of life for individuals affected by these debilitating conditions. By focusing on medical research, the Trust seeks to contribute to scientific breakthroughs that can lead to more effective treatments and, ultimately, cures. The program's scope is nationwide, indicating a broad commitment to supporting research efforts across all states and counties. The primary target beneficiaries of this grant program are 501(c)(3) organizations that are actively engaged in medical research related to leukemia, muscular dystrophy, and cerebral palsy. The ultimate impact goal is to foster significant advancements in these fields, leading to improved health outcomes for patients. The program prioritizes research that holds promise for developing new diagnostic tools, therapeutic interventions, and preventative strategies. While specific expected outcomes and measurable results are not detailed in the provided information, the overarching aim is to generate new knowledge, develop innovative treatments, and reduce the burden of these diseases on individuals and healthcare systems. The Ella B. Cleveland Trust's strategic priorities are clearly centered on health, specifically through medical research. The theory of change underpinning this program is that by providing financial support to qualified research organizations, the Trust can accelerate the pace of discovery and translate scientific findings into tangible benefits for patients. This approach emphasizes the critical role of well-funded research in driving progress against complex medical conditions. The limitation to 501(c)(3) organizations ensures that the grants are directed to established and reputable entities committed to public benefit. To be eligible for funding, organizations must meet the strict requirement of qualifying as exempt organizations under Section 501(c)(3) of the Internal Revenue Code. This ensures accountability and adherence to charitable purposes. While the size of individual grants and their duration are not specified, the program's consistent focus on these three critical diseases underscores a long-term commitment to making a substantial difference in these areas. The application deadline of June 30, 2024, indicates a structured timeline for funding cycles, allowing research institutions to plan their proposals accordingly.